Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05LFC
|
||||
| Former ID |
DIB018089
|
||||
| Drug Name |
(R)-PIA
|
||||
| Synonyms |
(R)-PIA; phenylisopropyladenosine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H23N5O4
|
||||
| InChI |
InChI=1S/C19H23N5O4/c1-11(7-12-5-3-2-4-6-12)23-17-14-18(21-9-20-17)24(10-22-14)19-16(27)15(26)13(8-25)28-19/h2-6,9-11,13,15-16,19,25-27H,7-8H2,1H3,(H,20,21,23)/t11-,13-,15-,16-,19-/m1/s1
|
||||
| InChIKey |
RIRGCFBBHQEQQH-SSFGXONLSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7978519, 10225878, 14804889, 26755712, 44423966, 47285807, 47434799, 47583679, 47583680, 47954402, 48029590, 49865128, 50111193, 56463445, 57335575, 80386480, 90340998, 103378209, 103837139, 104012073, 104409516, 124801205, 129134885, 134344406, 135052013, 135651557, 140033785, 143178674, 162249608, 163126327, 184561204, 188627620, 234368130, 241067965, 252377530
|
||||
| Target and Pathway | |||||
| Target(s) | Adenosine A2b receptor | Target Info | Agonist | [2] | |
| Adenosine A3 receptor | Target Info | Agonist | [3] | ||
| Adenosine A1 receptor | Target Info | Agonist | [4] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| Calcium signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Alcoholismhsa04022:cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| TCR Signaling PathwayNetPath_11:TCR Signaling Pathway | |||||
| RANKL Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Pathway Interaction Database | C-MYB transcription factor network | ||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | ||||
| Reactome | Adenosine P1 receptors | ||||
| G alpha (s) signalling events | |||||
| Surfactant metabolismR-HSA-417973:Adenosine P1 receptors | |||||
| G alpha (i) signalling eventsR-HSA-417973:Adenosine P1 receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP80:Nucleotide GPCRs | |||||
| GPCRs, OtherWP80:Nucleotide GPCRs | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 414). | ||||
| REF 2 | Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol. 1980 Jun;58(6):673-91. | ||||
| REF 3 | Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. Pharmacology. 1993;46(2):91-100. | ||||
| REF 4 | Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):1-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.